Modality
Fusion Protein
MOA
TROP-2 ADC
Target
CD3
Pathway
Hedgehog
CKDMDSParkinson's
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
Nov 2022
→ Jul 2031
Phase 1Current
NCT08632677
1,410 pts·CKD
2022-11→2031-07·Not yet recruiting
1,410 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-155.3y awayInterim· CKD
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Not yet…
Catalysts
Interim
2031-07-15 · 5.3y away
CKD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08632677 | Phase 1 | CKD | Not yet recr... | 1410 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 |